HSGC(SH:600774)2021-10-29 16:00Financial Performance - The company's operating revenue for Q3 2021 was CNY 371,431,434.41, representing a year-on-year increase of 442.70%[3] - The net profit attributable to shareholders of the listed company was CNY 16,095,649.84, with a year-to-date net profit of CNY 58,099,455.89[3] - The company reported a basic earnings per share of CNY 0.071 for Q3 2021, with a year-to-date figure of CNY 0.256[3] - Total operating revenue for the first three quarters of 2021 reached ¥1,109,718,413.83, a significant increase from ¥158,066,891.51 in the same period of 2020, representing a growth of approximately 600%[17] - The net profit for the first three quarters of 2021 was ¥57,121,353.24, a turnaround from a net loss of ¥96,635,547.47 in the same period of 2020[18] - Earnings per share for the first three quarters of 2021 were ¥0.2560, compared to a loss per share of ¥0.3089 in the previous year[18] - The company achieved an operating profit of ¥68,894,391.35 for the first three quarters of 2021, compared to an operating loss of ¥101,363,112.27 in the same period of 2020[17] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,878,811,771.16, an increase of 19.43% compared to the end of the previous year[4] - As of September 30, 2021, the company's total assets reached RMB 3,878,811,771.16, an increase from RMB 3,247,673,152.04 at the end of 2020[12] - The total liabilities as of September 30, 2021, amounted to ¥2,087,846,812.41, down from ¥2,412,926,964.55 at the end of 2020[14] - Total equity increased to ¥1,790,964,958.75 as of September 30, 2021, compared to ¥834,746,187.49 at the end of 2020, reflecting a growth of approximately 114%[14] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 214,846,984.88[3] - Cash inflow from operating activities for the first three quarters of 2021 reached ¥1,963,724,997.18, a significant increase from ¥508,461,325.09 in the same period of 2020, representing a growth of approximately 286%[21] - The net cash flow from operating activities was ¥214,846,984.88, compared to a negative cash flow of ¥27,541,361.51 in the first three quarters of 2020, indicating a turnaround in operational performance[21] - The company’s cash flow from operating activities showed a strong recovery, with a net increase of ¥649,289,305.50 in cash and cash equivalents during the period[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,315[8] - The largest shareholder, Wuhan Hanyang Investment Development Group Co., Ltd., held 26.93% of the shares[8] Subsidiaries and Market Activity - The company added a new subsidiary, Chengdu Dikan Pharmaceutical Co., Ltd., which generated operating revenue of CNY 830,950,368.04 and a net profit of CNY 94,447,002.79 for the year-to-date[6] - The company experienced a 602.06% increase in operating revenue compared to the same period last year, attributed to the addition of new subsidiaries and market recovery post-pandemic[5] Costs and Expenses - Total operating costs for the first three quarters of 2021 were ¥1,054,624,328.35, compared to ¥259,863,749.49 in the previous year, indicating a rise of about 305%[17] - The company reported a significant increase in research and development expenses, totaling ¥23,232,414.86 for the first three quarters of 2021[17] Cash and Equivalents - The company's cash and cash equivalents amounted to RMB 978,690,436.16, significantly up from RMB 329,401,130.66 in December 2020, indicating a growth of approximately 196%[12] - The ending balance of cash and cash equivalents was ¥978,690,436.16, up from ¥245,301,026.25 at the end of the third quarter of 2020, marking an increase of approximately 298%[22] Inventory and Receivables - Accounts receivable decreased to RMB 245,538,182.70 from RMB 276,124,192.43, reflecting a decline of about 11%[12] - Inventory increased to RMB 160,890,427.07, up from RMB 118,582,223.67, representing a growth of approximately 36%[12] - The company reported a significant increase in other receivables, which rose to RMB 106,721,752.16 from RMB 43,309,731.24, marking an increase of approximately 147%[12] Borrowings - Current liabilities decreased to RMB 1,279,405,011.53 from RMB 1,914,818,904.96, a reduction of about 33%[13] - Short-term borrowings were reduced to RMB 454,000,000.00 from RMB 662,000,000.00, indicating a decrease of approximately 31%[13] - Long-term borrowings increased to RMB 754,500,000.00 from RMB 441,400,000.00, reflecting an increase of about 71%[13] Other Information - The company did not report any significant new product launches or technological advancements during this period[24]